Tango Therapeutics logo

Tango Therapeutics

TNGX | NASDAQ
Chart Builder DCF Calculator
$24.17
-$1.33 (-5.22%)
At close: Nov 16, 2026, 4:00 PM ET
$24.22
+$0.05 (+0.21%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.22%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
28.4
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #843/1021 (Top 83%)

Key Statistics

Market Data

Market Cap $4.1B
1D Range
24.15 25.87
52W Range
7.98 32.90

Valuation (TTM)

PE -17.51
PB 4.18
EV/EBITDA -15.27

Valuation (NTM)

Forward PE N/A
Forward PEG -0.26
Price Target $46.50
Loading financial charts...

Profile

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small mol...

Sector Healthcare
Industry Biotechnology
Employees 137
IPO Date Sep 3, 2020
Fiscal Year January - December

Latest News

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

8 days ago · globenewswire.com

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference

14 days ago · globenewswire.com

Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying

19 days ago · seekingalpha.com

Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

22 days ago · zacks.com

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

24 days ago · seekingalpha.com

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate

25 days ago · marketbeat.com

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

25 days ago · benzinga.com

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug

25 days ago · investors.com

Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

25 days ago · globenewswire.com

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

2 months ago · zacks.com

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Earnings

Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$46.50
Upside
+92.39%
Buy (10)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.